<DOC>
	<DOC>NCT01686529</DOC>
	<brief_summary>The aim of this study was to investigate the efficacy and safety of subconjunctival bevacizumab application as an adjuvant therapy for primary pterygium.</brief_summary>
	<brief_title>Bevacizumab for Primary Pterygium Treatment</brief_title>
	<detailed_description />
	<mesh_term>Pterygium</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<criteria>Patients with primary pterygium Patients with diabetes mellitus collagenopathies, previous ocular surgeries, pregnant or lactating patients</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Pterygium</keyword>
	<keyword>bevacizumab</keyword>
	<keyword>autoconjunctival graft</keyword>
</DOC>